Royalty Pharma
RPRX
313 hedge funds and large institutions have $8.17B invested in Royalty Pharma in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 138 increasing their positions, 114 reducing their positions, and 46 closing their positions.
244% more call options, than puts
Call options by funds: $40.5M | Put options by funds: $11.8M
21% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 114
4% less funds holding
Funds holding: 325 → 313 (-12)
4.6% less ownership
Funds ownership: 71.36% → 66.76% (-4.6%)
12% less capital invested
Capital invested by funds: $9.32B → $8.17B (-$1.16B)
24% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 46
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.3M |
| 2 |
Two Sigma Investments
New York
|
+$31.9M |
| 3 |
Two Sigma Advisers
New York
|
+$31.2M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$31.1M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$27.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SVCF
Silicon Valley Community Foundation
Mountain View,
California
|
-$486M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$103M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$63.4M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$48.8M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$38.6M |
RPRX Hedge Fund Activity: Q3 2023 in Review
313 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2023, worth a combined $8.17B — down 12% from $9.32B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of RPRX and 35 opened new positions — a net loss of 11 holders — while 114 trimmed existing stakes and 138 added.
The largest buyer was Adage Capital Partners, adding an estimated $35.3M. The largest seller was Silicon Valley Community Foundation, cutting an estimated $486M.
- 313 institutional investors held Royalty Pharma (RPRX) as of Q3 2023, down from 325 in Q2 2023.
- Funds reported $8.17B of Royalty Pharma stock for Q3 2023, down 12% quarter-over-quarter.
- 35 funds opened new Royalty Pharma positions in Q3 2023 and 46 closed out, a net change of -11 holders.
- The largest Royalty Pharma buyer in Q3 2023 was Adage Capital Partners, an estimated $35.3M added.
- The largest Royalty Pharma seller in Q3 2023 was Silicon Valley Community Foundation, an estimated $486M sold.
Based on aggregated 13F filings for Q3 2023.